CLAIMS

1. Use of a proton pump regulator in the preparation of a reagent for preventing and/or treating a disease, wherein the proton pump regulator regulates ATP6V1B2 and/or a functionally active fragment thereof, and the disease comprises a stroke, and the proton pump regulator comprises the amino acid sequence set forth in SEQ ID NO: 33.

2. The use according to claim 1, wherein the stroke includes ischemic stroke and/or hemorrhagic stroke.

3. The use according to claim 12, wherein the ischemic stroke includes cerebral infarction, and the cerebral infarction includes lacunar infarction, ischemic cerebral infarction and/or hemorrhagic infarction.

4. The use according to any one of claims 2-3, wherein the ischemic stroke is caused by factors including: thrombus, embolism and/or hypotension, wherein the thrombus is caused by factors including: atherosclerosis, aneurysm, vascular malformation, arteritis and/or vasospasm.

5. The use according to any one of claims 2-4, wherein the ischemic stroke includes large artery atherosclerosis stroke, cardiogenic embolic stroke, small artery occlusion stroke, stroke of other determined etiology and/or stroke of undetermined etiology.

6. The use according to any one of claims 2-5, wherein the hemorrhagic stroke includes:

(i) brain parenchymal hemorrhage, intraventricular hemorrhage and/or subarachnoid hemorrhage, and

(ii) primary cerebral hemorrhage and/or secondary cerebral hemorrhage.

7. The use according to any one of claims 2-6, wherein the hemorrhagic stroke is caused by factors including: vascular malformation, aneurysm, blood disease, cerebral amyloid angiopathy, moyamoya disease, cerebral arteritis, anticoagulation or thrombolytic therapy and/or tumor stroke.

8. The use according to any one of claims 1-7, wherein the stroke includes stroke-induced impairments, the impairment includes impairment observed through imaging, impairment of learning ability, and the learning ability comprises cognitive ability, motor ability, memory ability, and/or spatial exploration ability;

wherein the impairment observed through imaging includes intracerebral hematoma, intraventricular hemorrhage, subarachnoid hemorrhage, edema, hematoma, mass effect, dense artery sign, insular ribbon sign, blurred or decreased density of the basal ganglia, and/or occlusion of small penetrating cerebral arteries.

9. The use according to any one of claims 1-8, wherein:

(a) the proton pump regulator is capable of improving the expression level and/or activity of the ATP6V1B2 in a subject, and wherein the improvement comprises, compared to the original expression level and/or activity of the ATP6V1B2 in the subject, improving the expression level and/or activity of the ATP6V1B2 by at least about 10%;

(b) the proton pump regulator is capable of increasing the release of neurotransmitters at neuronal synapses, and the increase includes an increase of at least about 10% compared to the original level of neurotransmitter release at neuronal synapses in the subject; and/or

(c) the proton pump regulator is capable of increasing the release frequency of excitatory postsynaptic currents, and the increase includes an increase of at least about 10% compared to the original level of release frequency of excitatory postsynaptic currents in the subject.

10. The use according to any one of claims 1-9, wherein the proton pump regulator comprise the amino acid sequence set forth in any one of SEQ ID NOs: 19-32.

11. The use according to any one of claims 1-10, wherein the proton pump regulator includes fusion protein and/or fusion polypeptide, wherein the fusion protein and/or fusion polypeptide comprise a molecule capable of being transported across the blood-brain barrier to the brain and the molecule capable of being transported across the blood-brain barrier to the brain comprises a cell-penetrating peptide.

12. The use according to claim 11, wherein the cell-penetrating peptide comprises the amino acid sequence set forth in SEQ ID NO: 34.

13. The use according to any one of claims 1-12, wherein the proton pump regulator comprises the amino acid sequence set forth in any one of SEQ ID NO: 35-48, .

14. The use according to any one of claims 1-13, wherein the subject includes mammals.

15. The use according to any one of claims 1-14, wherein the reagent is formulated to be suitable for oral administration and/or injection administration.